Kornimate/medical-research-clean huggingface dataset:
effectiveness of platelet-rich plasma treatment of knee osteoarthritis

Conditions: Knee Osteoarthritis

Summary: osteoarthritis (oa) is a disease that affects the joints of the body, causing pain, stiffness, and reduced mobility. to treat knee oa, a therapy called platelet-rich plasma (prp) is used, which involves making a concentrated substance from the patient's own blood and injecting it into the joint. it has been shown that this therapy is effective in reducing pain; however, more research is needed to optimize the preparation and identify which patients are more receptive to the treatment. the primary objective of this study is to evaluate two modalities of prp application and determine whether these treatments result in better pain reduction and improved functionality. the secondary objective is to explore the association between changes in lefs questionnaire scores and/or maximal quadriceps isometric strength and possible clinical improvement.


Eligibility criteria:
inclusion criteria: * radiological diagnosis of knee oa * age over 35 years old * womac value of 24 or higher at the time of recruitment exclusion criteria: * patients with knee prosthesis, rheumatoid arthritis, contralateral lower limb amputation, any type of blood dyscrasia, hypofibrinogenemia, depot pool syndrome, or any other form of thrombocytopathy or chronic leukocytosis will be excluded from the study. * patients with anticoagulant or acute coagulopathies, as well as carriers of any infectious disease or superficial infection at the puncture site, will be temporarily excluded from the study until their clinical recovery is confirmed by laboratory testing.

Keywords: autologous treatments public health lower extremity argentina real-world studies
safety and efficacy of imatinib added to chemotherapy in treatment of ph+ acute lymphoblastic leukemia in children

Conditions: Acute Lymphoblastic Leukemia; Philadelphia Chromosome

Summary: the purpose of this study is to determine whether imatinib is safe and effective in association with intensive treatment of ph+all in children.

recent advances in treatment have increased the cure of childhood all to 75% or better. however, attempts to improve results for resistant subtypes of all, such as ph+ all, have been largely unsuccessful. imatinib, an inhibitor of protein-tyrosine kinases, is currently being tested in several phase i, ii and iii trials covering most chronic myeloid leukemia patient populations and patients with overtly relapsed or refractory ph+all. pediatric patients with ph+all will receive imatinib, added to intensive, post-induction bfm-type chemotherapy. the endpoint will be the evaluation on the long-term clinical outcome, in particular on the disease free survival (dfs).

Eligibility criteria:
inclusion criteria: * children and adolescents aged 1 to 17 years at diagnostic * documented ph+ all * eligibility for the current local prospective therapeutic study of childhood all * informed consent given by the parents or by legal guardian exclusion criteria: * abnormal hepatic functions * abnormal renal functions * active systemic bacterial, fungal or viral infection

Keywords: chemotherapy leukemia children philadelphia chromosome protein-tyrosine kinase inhibitor
nitrofurantoin macrocrystals 3 days versus 7 days in the treatment of women with uncomplicated cystitis

Conditions: Cystitis

Summary: our guidelines in the community recommend the use of nm for the treatment of women with community acquired uti. while the length of treatment for uncomplicated cystitis with quinolones or tmp-smx is three days, nm is recommended for seven days. however, there are not sufficient papers that establish the optimal length of treatment with nm in this population. the aim of this proposal is to evaluate and compare nm 3 day vs. 7 day treatment for the treatment of women with uncomplicated uti.

the aim of this proposal is to evaluate and compare nm 3 day vs. 7 day treatment for the treatment of women with uncomplicated uti. our design is to enroll 400 women with uncomplicated cystitis and divided according to a double-blind randomization in two groups (3 days vs. 7 days). the women will be followed 7 days and 28 days clinically and bacteriologically.

Eligibility criteria:
inclusion criteria: 1. premenopausal healthy women 2. uncomplicated cystitis exclusion criteria: 1. postmenopausal women 2. complicated uti 3. women with catheter 4. women with recurrent uti 5. pregnancy 6. diabetes mellitus

Keywords: uncomplicated cystitis nitrofurantoin macrocrystals
treatment effect of cross-frequency transcranial alternating current stimulation on the mud

Conditions: Amphetamine-Related Disorders

Summary: the purpose of this research is to evaluate the efficacy of multiple sessions of theta-gamma cross-frequency transcranial alternating current stimulation in patients with methamphetamine (ma) use disorders.

previous evidence suggests that different aspects of cognitive function are associated with activities of distinct eeg frequency bands. gamma oscillatory has been found in clinical studies to reflect the processing of rewards in patients with drug dependence, whereas medial prefrontal theta oscillatory characterizes prefrontal response inhibition capacity to downstream reward arousal. interestingly, impaired response inhibition or impaired evaluation of rewards in patients with drug dependence have been found to correlate with the arousal of psychological craving and the emergence of relapse. here we aim to find causal evidence supporting these previous correlational findings by applying cross-frequency transcranial alternating current stimulation (tacs) in the specific frequency bands (theta-gamma) previously shown to be addiction-relevant. in a randomized control clinical trial design, we stimulate subjects with either theta-gamma or sham tacs. electroencephalography will be collected before and after each treatment session. besides, the scale and behavior task data will also collected before and after the treatment.

Eligibility criteria:
inclusion criteria: 1. in accordance with the diagnostic and statistical manual of mental disorders-5 (dsm-5) for methamphetamine (ma) use disorders 2. normal vision and hearing 3. dextromanual 4. use ma not less than 1 year, and the last of ma use no less than 3 months exclusion criteria: 1. have a disease that affects cognitive function such as a history of head injury, cerebrovascular disease, epilepsy, etc 2. have cognitive-promoting drugs in the last 6 months 3. other substance abuse or dependence in recent five years (except nicotine) 4. meet the dsm-5 criteria for other mental disorders 5. physical disease
evaluating the utility of continuous positive airway pressure in the treatment of high altitude pulmonary edema

Conditions: Continuous Positive Airway Pressure; High Altitude Pulmonary Edema

Summary: the primary objective is to evaluate the efficacy of continuous positive pressure on resolution of high-altitude pulmonary edema vs high flow oxygen. the secondary objective is to derive an incidence of high-altitude pulmonary edema based on the elevation and timing from which the subject arrives. additionally, in a convenience sample of the base study population, an ultrasound evaluation for the presence of b lines in the lungs will be conducted after 2 hours.

multicenter, double-blinded, randomized control trial. enrollment is based on presentation to one of the treating facilities with clinical signs and symptoms of high-altitude pulmonary edema with a recent arrival at high altitude, an oxygen saturation below 85%, and radiographic evidence of noncardiogenic pulmonary edema. a total of 264 patients will be randomized 1:1 across 2 study arms: a cpap mask set to 15cm h2o and an altered cpap mask in which the pressure valve has been modified to deliver no positive pressure. all patients will be treated with 30mg nifedipine xr. except for the application of positive pressure, all other interventions are performed in the context of everyday clinical practice, and thus will be equivalent for participants in both arms. patients will be evaluated every 30 minutes for their ability to maintain an oxygen saturation of 92% with a normal respiratory rate and no signs of increased work of breathing on 2 liters of nasal cannula oxygen for a total of up to a maximum treatment length of 2 hours. the primary efficacy endpoint will be assessed every 30 minutes for 2 hours.

Eligibility criteria:
inclusion criteria: * male or female, age 18 years or greater * oxygen saturation below 85% * recent arrival to high altitude * dyspnea and cough * xray revealing non-cardiogenic pulmonary edema exclusion criteria: * pregnancy * age below 18 * patients with respiratory failure requiring intubation * patients with altered mental status * patients with impaired decision-making capacity * patients with a history of congestive heart failure, cad, copd, asthma, known current pneumonia * extreme facial hair precluding application of cpap
bioequivalence study for gemigliptin/metformin 50/1000 mg and coadministration of gemigliptin 50 mg and metformin 1000 mg.

Conditions: Type2 Diabetes

Summary: \[objectives\]primary: to determine and compare the rate and extent of absorption of gemigliptin/metformin hydrochloride sustained release 50/1000 mg fdc tablet (zemimet® sr tab. 50/1000 mg) and coadministration of corresponding dose of gemigliptin 50 mg (zemiglo tablet 50 mg) and metformin hydrochloride 1000 mg prolonged release (glucophage xr 1000 mg) as individual tablet in healthy subjects under fasting conditions secondary: to evaluate safety of test and reference formulations


Eligibility criteria:
inclusion criteria: * body mass index between 18.0 to 30.0 kg/m2. * normal laboratory values, including vital signs and physical examination, for all parameters in clinical laboratory tests at screening. * non-pregnant woman (negative pregnancy test) and not currently breast feeding * female subjects abstain from either hormonal methods of contraception * male subjects who are willing or able to use effective contraceptive * have voluntarily given written informed consent (signed and dated) by the subject prior to participating in this study. exclusion criteria: * history serious hypersensitivity reactions * history or evidence of clinically significant diseases or any significant ongoing chronic medical illness * history or evidence of family diabetes * history or evidence of type 1 diabetes mellitus, diabetic ketoacidosis, diabetic pre-coma * history or evidence of shock or severe dehydrate or severe infection * history or evidence of preceding diarrhea or vomiting within 24 hours prior to admission in each period * history or evidence of drug addict or investigation with urine sample shows a positive test for drug of abuse * history of problems with swallowing tablet or capsule * history of sensitivity to heparin or heparin-induced thrombocytopenia * any condition possibly affecting drug absorption * have renal creatinine clearance (clcr) \< 45 ml/min based on serum creatinine results at the screening laboratory test * 12-lead ecg demonstrating qtc \>450 msec, a qrs interval \>120 msec or with an abnormality considered clinically significant at screening
transvaginal ultrasound in women with abnormal uterine bleeding

Conditions: Abnormal Uterine Bleeding

Summary: the objective of this study is to investigate the role of transvaginal ultrasound in detecting endometrial hyperplasia and endometrial cancer in women aged more than 35 presenting with abnormal uterine bleeding.


Eligibility criteria:
inclusion criteria: * premenopausal women aged over than 35 * abnormal uterine bleeding (menorrhagia/menometrorrhagia/metrorrhagia) * accept transvaginal examination (pelvic examination and ultrasound) * informed consent exclusion criteria: * severe uterine bleeding resulting in unstable vital signs * pregnancy * current medications: anticoagulants, selective serotonin reuptake inhibitor (ssri), antipsychotics, corticosteroids, hormones, herbs * intrauterine device * genital tract pathologies: infection, submucous myoma distorting uterine cavity * systemic diseases that may cause coagulopathies: thyroid disease, liver disease, pituitary/ hypothalamus diseases * not able to retrieve endometrial tissue

Keywords: transvaginal sonography endometrial thickness endometrial pattern abnormal uterine bleeding endometrial hyperplasia endometrial cancer
endometrial scratching during laproscopic ovarian drilling in subfertile pcos women

Conditions: Infertility; Polycystic Ovarian Syndrome

Summary: laparoscopic ovarian drilling is a valid procedure for infertile anovulatory women with polycystic ovarian syndrome who failed to get pregnant or to ovulate with ovulation induction medications as clomiphene citrate or exogenous gonadotropins. the reasearchers supposed that endometrial curettage at time of laparoscopic ovarian drilling may boost fertility in these women.

current literature suggests that endometrial biopsy may improve pregnancy rates in infertile women hence the investigators will examine whether this hypothesis will apply to infertile pcos women undergoing laparoscopic ovarian drilling to overcome ovulatory disfunction or not.

Eligibility criteria:
inclusion criteria: 1. subfertile women with anovulatory infertility due to polycystic ovarian syndrome (pcos). 2. women who failed to get pregnant after at least 6 months of ovulation induction cycles with clomiphene citrate or exogenous gonadotropins 3. patent fallopian tubes as confirmed by hysterosalpingography 4. fertile semen parameters of the partneraccording to criteria of world health organization (who 2010). exclusion criteria: 1. women with bmi \>30, 2. age \ 39 years, 3. women with ovarian cysts identified by transvaginal ultrasound 4. male factor infertility 5. tubal factor infertility as suggested by hystrosalpingogram (hsg) 6. women with congenital malformations in the uterus as bicornuate or septate uterus as suggested by hsg.

Keywords: infertility pcos scratching endometrial receptivity
fluid lavage of open wounds

Conditions: Open Fracture Wounds

Summary: open fracture wounds are a constant challenge to orthopaedic surgeons, with infections a common complication. there is currently little evidence as to which is the most effective way to wash out these wounds. this study is a multi-center, prospective, randomized study. the infection rates will be compared between irrigation using high pressure versus low pressure versus gravity flow, and also saline versus a soap solution as the irrigation solution. the results from this study will help to determine the best method of washing out open fractures wounds. in this study, all open wounds will be washed out using methods commonly used by orthopaedic surgeons


Eligibility criteria:
inclusion criteria: 1. men or women who are skeletally mature. 2. fracture of any extremity with complete radiographs. 3. open fractures (gustilo-anderson types i-iiib) (table 2)\*. 4. fracture requiring operative fixation. 5. provision of informed consent. exclusion criteria: 1. open fractures with an associated vascular deficit (gustilo-anderson type iiic). 2. known allergy to detergents or castile soap ingredients. 3. previous wound infection or history of osteomyelitis in the injured extremity. 4. previous fracture with retained hardware in injured extremity that will interfere with new implant fixation. 5. surgical delay to operative wound management greater than 24 hours from hospital admission. 6. use of immunosuppressive medication within 6 months. 7. immunological deficient disease conditions (e.g. hiv). 8. fracture of the hand (metacarpals and phalanges). 9. fracture of the toes (phalanges). 10. likely problems, in the judgment of the investigators, with maintaining follow-up. we will, for example, exclude patients with no fixed address, those who report a plan to move out of town in the next year, or intellectually challenged patients without adequate family support. 11. previous randomization in this study or a competing study.
assessment of exam findings in coronavirus disease 2019 (covid-19) with point-of-care ultrasonography (pocus)

Conditions: Coronavirus Infection; COVID; Covid-19; SARS-CoV-2

Summary: specific aims: 1. the investigators will prospectively evaluate and analyze changes in the appearance of the lungs and heart through serial acquisition of focused point-of-care ultrasound images in a cohort of patients with or under investigation for covid-19. 2. the investigators will correlate changes noted in ultrasound with clinical course and diagnostic evaluation to ascertain whether changes on ultrasound could improve care through earlier diagnosis or identification of patients at high risk of disease progression.

the investigators will perform a descriptive study aimed at identifying the cardiopulmonary ultrasound features in patients with or under investigation for covid-19. the study will take place at two sites: university of minnesota medical center (ummc) and bethesda hospital. at ummc, a tertiary care center, clinicians will recruit and evaluate patients with or under investigation for covid-19. at bethesda clinicians will recruit and evaluate patients with a confirmed diagnosis of covid-19 as demonstrated by a positive pt-pcr. pocus exams will be performed in a cohort of 200-500 patients with or under investigation for covid-19. serial ultrasound examinations will be performed every 48-72 hours until discharge, death, or study completion. participants will undergo pocus at enrollment by their treating physicians. inquiry into study enrollment will be performed over the phone rather than in person, given the current scarcity of ppe and the added use that would occur with in-person enrollment.

Eligibility criteria:
inclusion criteria: * patients under investigation for covid-19 * patients that are positive for covid-19 at ummc and bethesda exclusion criteria: - ultrasound contraindication such as overlying skin wound
clear care companion application

Conditions: Bladder Cancer; Radical Cystectomy

Summary: hospital readmissions are common after major cancer surgery, leading to poorer patient outcomes, increased mortality and additional costs. in this study, clinical and engineering approaches to readmission (clear) care companion application, investigators aim to utilize a smartphone application that tracks concerning postoperative symptoms and provides educational interventions to determine if this can minimize delays in communication between patients and medical providers, increase patient satisfaction with the care received, and reduce or lessen the severity of readmissions.

patients complete clinically meaningful questions and validated questionnaires pertaining to physiological and psychological symptoms that serve as early indicators of readmission, with the aim to improve experience by empowering patient to be active participants in their recovery, identify complications early to minimize morbidity and reduce overall readmissions. the study has the following three objectives: (1) assess patient engagement with the clear care companion application for patients that have undergone radical cystectomy (2) measure patient experience with the application and its effect on satisfaction with overall care (3) evaluate the effect of the application on case complexity (readmission intensity) and overall readmission rates.

Eligibility criteria:
inclusion criteria: * patients undergoing a radical cystectomy with reconstruction through gu oncology clinic * patient at the university of michigan (michigan medicine) * access to compatible smartphone or tablet device exclusion criteria: * non-english speaking patients * patients without access to a smart phone or tablet with internet capacity

Keywords: mobile application post surgical care
a study of eras-4001 in patients with advanced or metastatic solid tumors.

Conditions: Metastatic Solid Tumors

Summary: the main purpose of the study is to assess whether the study drug, eras-4001, is safe and tolerable when administered to patients with advanced or metastatic solid tumors with certain kras mutations. eras-4001 will be given alone or in combination with other treatments.

this is a first-in-human, phase 1/1b, open-label, multicenter clinical study of eras-4001 as a monotherapy and in combination with other cancer therapies. the study will commence with dose optimization of eras-4001 monotherapy, followed by dose optimization of eras-4001 in combination with other cancer therapies.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years * willing and able to give written informed consent * pathological documentation of tumor type and mutation prior to the first dose of study drug(s) * there is no available standard systemic therapy available for the patient's tumor histology and/or molecular biomarker profile; or standard therapy is intolerable, not effective, or not accessible; or patient has refused standard therapy * able to swallow oral medication * have eastern cooperative oncology group performance status (ecog ps) of 0 or 1 * adequate cardiovascular, hematological, liver, and renal function * willing to comply with all protocol-required visits, assessments, and procedures exclusion criteria: * previous treatment with a ras inhibitor * is currently receiving another study therapy or has participated in a study of an investigational agent and received study therapy within 4 weeks of the first dose of eras-4001 * received prior palliative radiation within 14 days of cycle 1, day 1 * have primary central nervous system (cns) tumors * prior surgery (e.g., gastric bypass surgery, gastrectomy) or gastrointestinal dysfunction (e.g., crohn's disease, ulcerative colitis, short gut syndrome) that may affect drug absorption * have any underlying medical condition, psychiatric condition, or social situation that, in the opinion of the investigator, would compromise study administration as per protocol or compromise the assessment of aes * are pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the trial

Keywords: solid tumor advanced solid tumor solid malignancies targeted therapy molecular alterations pembrolizumab keytruda panitumumab vectibix metastatic solid tumor neoplasms